Our Technologies

Our commitment to innovative research spans a wide spectrum of technologies. From uncovering novel therapeutic targets and pioneering precise diagnostics platforms to harnessing the power of artificial intelligence to expedite the pace of discovery, we push the boundaries of what’s possible in the fight against cancer and related disease.

Showing 37-48 of 51

Methods for Modulating MHC-I Expression in Merkel Cell Carcinoma

Licensing

Antisense Inhibitors of Long Noncoding RNA as Treatment for Multiple Myeloma

Licensing

Highly Selective Focal Adhesion Kinase (FAK) Inhibitors

Licensing

Methods of Treating Cancers Using STING Agonists

Collaboration
Licensing

Enhanced Cell Immunotherapy Approach Using Multi-Specific Cytotoxic CD4+ T Cells

Licensing

Allosteric EGFR Inhibition May Improve Outcomes for Non-Small Cell Lung Cancer

Licensing

EGFR illustration in its inactive and active form

Targeting BFL-1 Reactivates Cancer Cell Death

Collaboration
Licensing

Microscopic view of damaged cells undergoing apoptosis

First-in-Class, Dual Degraders of IRAK 1 and IRAK 4 for MyD88-Mutant Blood Cancers

Collaboration
Licensing

Small Molecule Inhibitors for the Treatment of VEXAS Syndrome

Collaboration

Cancer Vaccine Prevents Tumor Formation and Metastasis by a Dual Immune Cell Attack

Licensing

DUB Drug Discovery: A Platform for Creating DUB-Focused Small Molecules to Regulate Protein Homeostasis in Human Disease

New Company

TransTAC: Next-Generation Targeted Protein Degradation Technology

Investment
Licensing

artist rendition of a bi-specific antibody binding to two molecules